Nov 3, 2003Conference Call and Webcast to be Held Today at 12:00 PM ET (18:00 CET)
BioMarin Pharmaceutical Inc. today announced financial results for its third quarter ended September 30, 2003. The net loss was $21.3 million ($0.33 per share) for the third quarter of 2003...
Sep 21, 2003BioMarin Halts Phase 3a Study of Neutralase in CABG and Terminates the Neutralase Drug Development ProgramBioMarin Spending Projected to Decrease in Both 2003 and 2004
BioMarin Pharmaceutical Inc. announced that it halted its Phase 3a study of Neutralase(TM) for the reversal of anticoagulation by heparin in primary Coronary Artery Bypass Graft (CABG) surgery and...
Sep 3, 2003Data Warrants Further Study of Intrathecal Injection of Enzyme for Treating Neurological Symptoms of MPS I
BioMarin Pharmaceutical Inc. announced results from studies indicating that intrathecal injection of recombinant human alpha-L-iduronidase (rhIDU) can reduce carbohydrate storage in brain tissue...